PDS Biotechnology Corporation (PDSB) Financial Statements (2024 and earlier)

Company Profile

Business Address 303A COLLEGE ROAD EAST
PRINCETON, NJ 08540
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments73,820,16065,242,62228,839,56512,161,73934,645,54988,067,647
Cash and cash equivalents73,820,16065,242,62228,839,56512,161,73934,645,54988,067,647
Other undisclosed current assets2,660,2301,597,5691,497,6652,308,4621,005,589986,680
Total current assets:76,480,39066,840,19130,337,23014,470,20135,651,13889,054,327
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization374,888   
Operating lease, right-of-use asset 152,645357,611547,706 
Property, plant and equipment 865,44321,051426,9523,423,880
Intangible assets, net (including goodwill)    2,974,000  
Intangible assets, net (excluding goodwill)    2,974,000  
Other noncurrent assets     142,870142,870
Other undisclosed noncurrent assets    (2,974,000)  
Total noncurrent assets:527,533357,697553,14921,051569,8223,566,750
TOTAL ASSETS:77,007,92367,197,88830,890,37914,491,25236,220,96092,621,077
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities9,532,9953,497,1073,150,5462,295,360818,5669,791,338
Accounts payable1,219,2871,309,4031,415,2241,197,720399,4474,369,133
Accrued liabilities8,313,7082,187,7041,735,3221,097,640419,1195,422,205
Debt56,612    3,075,421
Restructuring reserve    498,1855,563,186 
Other undisclosed current liabilities 231,429258,924119,904   
Total current liabilities:9,821,0363,756,0313,270,4502,793,5456,381,75212,866,759
Noncurrent Liabilities
Long-term debt and lease obligation23,184,857231,430490,353  17,382,907
Long-term debt, excluding current maturities23,020,844    17,382,907
Finance lease, liability164,013   
Operating lease, liability  231,430490,353 
Other undisclosed noncurrent liabilities  (231,430)(490,353)   
Total noncurrent liabilities:23,184,857231,430490,353  17,382,907
Total liabilities:33,005,8933,987,4613,760,8032,793,5456,381,75230,249,666
Equity
Equity, attributable to parent44,002,03063,210,42727,129,57611,697,70729,839,20862,371,411
Common stock9,9569,3877,3461,74210,59110,400
Additional paid in capital145,550,491123,904,60270,907,31540,633,670222,644,982214,309,370
Accumulated deficit(101,558,417)(60,703,562)(43,785,085)(28,937,705)(192,816,365)(151,948,359)
Total equity:44,002,03063,210,42727,129,57611,697,70729,839,20862,371,411
TOTAL LIABILITIES AND EQUITY:77,007,92367,197,88830,890,37914,491,25236,220,96092,621,077

Income Statement (P&L) (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Operating expenses(41,672,421)(21,439,311)(14,902,386)(21,034,618)(43,096,567)(51,966,620)
Operating loss:(41,672,421)(21,439,311)(14,902,386)(21,034,618)(43,096,567)(51,966,620)
Nonoperating income
(Investment Income, Nonoperating)
935,1804,34655,00613,688,058871,879700,903
Interest and debt expense(1,316,519)  (33,559)(1,425,255)(2,180,143)
Other undisclosed income from continuing operations before equity method investments, income taxes      
Loss from continuing operations before equity method investments, income taxes:(42,053,760)(21,434,965)(14,847,380)(7,380,119)(43,649,943)(53,445,860)
Other undisclosed loss from continuing operations before income taxes      
Loss from continuing operations before income taxes:(42,053,760)(21,434,965)(14,847,380)(7,380,119)(43,649,943)(53,445,860)
Income tax expense (benefit)1,198,9054,516,488 (381,513)2,781,9372,586,057
Loss from continuing operations:(40,854,855)(16,918,477)(14,847,380)(7,761,632)(40,868,006)(50,859,803)
Loss before gain (loss) on sale of properties:(16,918,477)(14,847,380)(7,761,632)(40,868,006)(50,859,803)
Net loss:(40,854,855)(16,918,477)(14,847,380)(7,761,632)(40,868,006)(50,859,803)
Other undisclosed net income attributable to parent    763,026  
Net loss available to common stockholders, diluted:(40,854,855)(16,918,477)(14,847,380)(6,998,606)(40,868,006)(50,859,803)

Comprehensive Income (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(40,854,855)(16,918,477)(14,847,380)(7,761,632)(40,868,006)(50,859,803)
Comprehensive loss:(40,854,855)(16,918,477)(14,847,380)(7,761,632)(40,868,006)(50,859,803)
Other undisclosed comprehensive income, net of tax, attributable to parent    763,015  
Comprehensive loss, net of tax, attributable to parent:(40,854,855)(16,918,477)(14,847,380)(6,998,617)(40,868,006)(50,859,803)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: